Neuroscience News2 天
Childhood Stress Disrupts Attention, Sleep, and Dopamine Balance in Adults
New research links childhood adversity with later attention deficits, sleep disruptions, and specific dopamine imbalances in ...
Delving into the causes of attention deficits: Childhood adversity, lost sleep and dopamine
New research on the effects of adversity in childhood ties together stress, sleep loss, and attention deficits later in life.
The American Journal of Managed Care4 天
Novel Orexin 2 Receptor Agonist Shows Promise for Management of Narcolepsy and Idiopathic ...
Brendon Yee, PhD, professor and respiratory and sleep physician, Woolcock Institute of Medical Research, discusses the ...
Dr. Friend Proposes the Potential for Non-Pharmacological Improvement of Sleep Disorders ...
- Paper published in the international SCI-level International Journal of Molecular Sciences (IJMS) on the 'Effects of ...
Pharmaceutical Technology6 天
NLS and Kadimastem stocks soar following merger agreement
The stocks for both Swiss and Israeli biotechs were up over 20% after the companies signed a merger agreement.
Stifel bullish on orexin, upgrades Alkermes to Buy
Stifel upgraded Alkermes (ALKS) to Buy from Hold with a price target of $36, up from $25. After a deep dive on the orexin space, the firm says ...
Stifel将Alkermes目标价上调至36美元，评级上调至买入
周一，Stifel对Alkermes (NASDAQ:ALKS)采取了看多行动，将其股票评级从持有上调至买入，并将目标价从之前的25美元大幅上调至36美元。这次上调是在对公司的orexin项目，特别是ALKS2680候选药物进行深入分析后做出的。 Stifel分析师强烈相信ALKS2680在治疗1型嗜睡症（NT1）方面的潜在成功，以及其与竞争对手TAK-861的差异化。这种乐观情绪还延伸到ALKS ...